The Trouble with Markers
Evaluating a potential anti-aging therapeutic poses a unique challenge. When the endpoint is natural death, assessing efficacy in a realistic timeframe requires a surrogate, but biomarkers for aging have been elusive.
"There are no biomarkers that are very good at predicting of subsequent longevity, and that is the gold standard of what a biomarker is," says Tom Johnson of the University of Colorado at Boulder. While clinical research still rests largely on physiological status such as diastolic function, some argue that genomics or proteomics may provide more precise molecular markers.
Researchers at the Washington University School of Medicine...
Interested in reading more?
Become a Member of
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member?